Form 4: Anebulo Pharmaceuticals Director Areta Kupchyk Granted Stock Options and Establishes Power of Attorney

Areta Kupchyk, a director at Anebulo Pharmaceuticals, was granted stock options and established a limited power of attorney for Section 16 reporting obligations.

Summary

• Areta Kupchyk, a director of Anebulo Pharmaceuticals, received stock options on June 13, 2024.
• She was granted 41,667 stock options that vest 50% on the date of the 2024 annual meeting of shareholders and 50% on the one-year anniversary of the grant date.
• Additionally, she received 1,324 stock options that vest on the earlier of November 30, 2024, or the date of the 2024 annual meeting of shareholders.
• The exercise price for both sets of options is $2.10, and they expire on June 12, 2034.
• Kupchyk also established a limited power of attorney, effective June 14, 2024, appointing Richard Cunningham or Daniel George of Anebulo Pharmaceuticals to handle SEC filings related to her stock ownership.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance practices and insider transactions, which are generally viewed neutrally to positively by investors as they align director interests with shareholders.

Positives

• The granting of stock options to a director aligns her interests with those of the shareholders.
• The establishment of a power of attorney simplifies the administrative process of SEC filings.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize directors and align their interests with shareholders. The establishment of a power of attorney for SEC filings is a standard administrative procedure.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the pharmaceutical industry, similar to companies like Pfizer, Johnson & Johnson, and Merck.
• The vesting schedules and exercise prices are generally in line with industry norms for incentivizing long-term performance.
• The use of a power of attorney for SEC filings is a standard procedure, comparable to practices at other publicly traded companies.

Stakeholder Impact

• Shareholders may view the stock option grants positively as they align the director's interests with the company's long-term success.
• The power of attorney simplifies administrative processes, potentially benefiting the company's efficiency.

Key Dates